^
    Apply
    Myeloma-Developing Regimens Using Genomics (MyDRUG) (NCT03732703)
    Phase 1/2
    Multiple Myeloma Research Consortium
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    04/01/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    BRAF • SLC1A5
    |
    Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623
    Biomarkers of AKI in Patients Receiving Daratumumab (NCT06549634)
    Phase N/A
    Brigham and Women's Hospital
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    09/01/2024
    Primary completion :
    09/01/2026
    Completion :
    10/01/2026
    DKK3
    |
    Darzalex (daratumumab)
    Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer (NCT03473730)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    01/30/2025
    Initiation :
    05/29/2018
    Primary completion :
    01/27/2025
    Completion :
    01/27/2025
    PD-L1
    |
    Darzalex (daratumumab)
    MUK Nine b: OPTIMUM Treatment Protocol (MUKnineb) (NCT03188172)
    Phase 2
    University of Leeds
    Active, not recruiting
    Last update posted :
    05/14/2024
    Initiation :
    09/28/2017
    Primary completion :
    10/01/2025
    Completion :
    05/31/2026
    CD34
    |
    lenalidomide • bortezomib • cyclophosphamide • Darzalex (daratumumab) • dexamethasone • melphalan • Neupogen (filgrastim)
    A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread (CheckMate142) (NCT02060188)
    Phase 2
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    05/10/2024
    Initiation :
    03/12/2014
    Primary completion :
    06/28/2024
    Completion :
    06/28/2024
    MSI
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cotellic (cobimetinib) • Darzalex (daratumumab) • relatlimab (BMS-986016)
    Neoadjuvant Listeria or Daratumumab in Prostate Cancer (NCT03035357)
    Phase 2
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    05/03/2024
    Initiation :
    03/01/2017
    Primary completion :
    03/01/2019
    Completion :
    03/01/2019
    CD68
    |
    Darzalex (daratumumab)
    A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation (NCT03556332)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    03/18/2024
    Initiation :
    07/02/2018
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    CD34
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • dexamethasone
    A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets (NCT05308654)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    01/25/2024
    Initiation :
    05/17/2022
    Primary completion :
    08/28/2026
    Completion :
    08/28/2026
    BCL2
    |
    Chr t(11;14)
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • ABBV-453
    FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia (NCT04714372)
    Phase 1
    Masonic Cancer Center, University of Minnesota
    Active, not recruiting
    Last update posted :
    01/10/2024
    Initiation :
    11/03/2021
    Primary completion :
    01/09/2024
    Completion :
    12/15/2025
    FLT3 • IDH1 • IDH2 • CD38
    |
    CD38 expression
    |
    cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538 • cyclophosphamide intravenous
    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (EAE120) (NCT05280275)
    Phase 1/2
    Hellenic Society of Hematology
    Recruiting
    Last update posted :
    12/01/2023
    Initiation :
    04/13/2022
    Primary completion :
    03/15/2026
    Completion :
    03/15/2026
    CD4
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)
    An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (CheckMate 039) (NCT01592370)
    Phase 1/2
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    09/13/2023
    Initiation :
    08/02/2012
    Primary completion :
    09/25/2020
    Completion :
    12/22/2023
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Darzalex (daratumumab) • dexamethasone • pomalidomide • lirilumab (BMS-986015)
    Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara (NCT03896737)
    Phase 2
    European Myeloma Network
    Active, not recruiting
    Last update posted :
    09/07/2023
    Initiation :
    04/16/2019
    Primary completion :
    05/01/2024
    Completion :
    02/01/2025
    IGH
    |
    IGH translocation
    |
    bortezomib • cyclophosphamide • Ninlaro (ixazomib) • Darzalex (daratumumab) • thalidomide • melphalan • cyclophosphamide intravenous
    A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma (AMC-105) (NCT04139304)
    Phase 1
    AIDS Malignancy Consortium
    Recruiting
    Last update posted :
    08/31/2023
    Initiation :
    05/24/2021
    Primary completion :
    07/31/2025
    Completion :
    08/01/2027
    CD4
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Darzalex (daratumumab) • vincristine • daunorubicin • cyclophosphamide intravenous
    Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT03346135)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    08/16/2023
    Initiation :
    07/17/2019
    Primary completion :
    07/17/2025
    Completion :
    07/17/2025
    CD34
    |
    Darzalex (daratumumab) • melphalan
    Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma (DETER-SMM) (NCT03937635)
    Phase 3
    ECOG-ACRIN Cancer Research Group
    Recruiting
    Last update posted :
    06/23/2023
    Initiation :
    09/16/2019
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    CD34
    |
    Chr t(4;14)
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone
    Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. (DILEMMA) (NCT05835726)
    Phase N/A
    Fondazione Policlinico Universitario Agostino G...
    Recruiting
    Last update posted :
    05/01/2023
    Initiation :
    01/01/2022
    Primary completion :
    12/31/2023
    Completion :
    04/30/2024
    CD38 • CD34
    |
    CD38 expression
    |
    bortezomib • Darzalex (daratumumab)
    A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia (NCT03187262)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    11/23/2022
    Initiation :
    11/27/2017
    Primary completion :
    01/31/2021
    Completion :
    12/31/2021
    EGFR
    |
    Darzalex (daratumumab)
    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory (NCT05581875)
    Phase 1/2
    Hellenic Society of Hematology
    Not yet recruiting
    Last update posted :
    10/17/2022
    Initiation :
    10/20/2022
    Primary completion :
    10/31/2026
    Completion :
    10/31/2026
    CD4
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53) (NCT03734198)
    Phase 2
    French Innovative Leukemia Organisation
    Active, not recruiting
    Last update posted :
    06/28/2022
    Initiation :
    12/19/2018
    Primary completion :
    06/01/2024
    Completion :
    06/01/2026
    TP53 • CD38
    |
    TP53 mutation • CD38 expression
    |
    Imbruvica (ibrutinib) • Darzalex (daratumumab)
    A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX) (NCT03023423)
    Phase 1b/2
    Janssen Research & Development, LLC
    Completed
    Last update posted :
    11/20/2019
    Initiation :
    12/23/2016
    Primary completion :
    05/17/2018
    Completion :
    09/26/2019
    PD-L1
    |
    Tecentriq (atezolizumab) • Darzalex (daratumumab)
    Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma (REBUILD) (NCT03475628)
    Phase 2
    Hellenic Society of Hematology
    Unknown status
    Last update posted :
    03/23/2018
    Initiation :
    02/21/2018
    Primary completion :
    06/20/2019
    Completion :
    02/20/2020
    DKK1 • CCL3
    |
    lenalidomide • Darzalex (daratumumab)